Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532779 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects
A Phase 3 study, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,742
- Enrollment target
NCT00532779 is a Phase 3 study that has completed, run by Orexigen Therapeutics. The registered enrollment target is 1,742 participants.
The verdict
NCT00532779, a Phase 3 study, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,742 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.
Interventions
- DRUG Placebo
- BEHAVIORAL Ancillary therapy
- DRUG Naltrexone SR 16 mg/Bupropion SR 360 mg /day
- DRUG Naltrexone SR 32 mg/Bupropion SR 360 mg /day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,742 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00532779
The ClinicalTrials.gov registry entry for NCT00532779 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,742 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orexigen Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00532779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00532779 about?
NCT00532779 is a clinical study titled "A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects". The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.
What is the current status of trial NCT00532779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,742 participants. The study started on 2007-10. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00532779?
The interventions under investigation include: Placebo (DRUG), Ancillary therapy (BEHAVIORAL), Naltrexone SR 16 mg/Bupropion SR 360 mg /day (DRUG), Naltrexone SR 32 mg/Bupropion SR 360 mg /day (DRUG).
Who is sponsoring clinical trial NCT00532779?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.